Výsledky vyhledávání - "Jennifer B. Lai"

Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007–2017

Autor: Jennifer O Lam, David J. Witt, Varun Saxena, Michael J. Silverberg, Leo B. Hurley, Scott Chamberland, Jamila H. Champsi, Jennifer B. Lai, Julia L. Marcus, Charles P. Quesenberry, Joanna Ready, Daniel G. Korn, Suk I. Seo

Publikováno v: Open Forum Infectious Diseases

Among 25 291 and 4 921 830 people with and without hepatitis C, life expectancy at age 20 increased 1.8 years and 0.3 years from the interferon to interferon-free era, respectively. Increases were highest for racial and/or ethnic minority groups with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77053fd336aa9b37d92aaf7b151fc713
https://doi.org/10.1093/ofid/ofaa044

Zobrazit plný text záznamu

No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients

Autor: Laura C. Gittleman, Michael J. Silverberg, Joanna Ready, Mary Patricia Pauly, Jennifer O Lam, Scott Chamberland, Daniel G. Korn, Julia L. Marcus, Jamila H. Champsi, Jennifer B. Lai, Suk I. Seo, Leo B. Hurley, Charles P. Quesenberry, Varun Saxena, David J. Witt

Publikováno v: Clinical Gastroenterology and Hepatology. 16:927-935

BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ca2f339f041c907cbeb67cacd24bf70
https://doi.org/10.1016/j.cgh.2018.03.003

Zobrazit plný text záznamu

Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in an Insured Population

Autor: Daniel G. Korn, Michael J. Silverberg, Joanna Ready, Julia L. Marcus, Varun Saxena, Jennifer O Lam, Leo B. Hurley, Scott Chamberland, Charles P. Quesenberry, Mary Pat Pauly, Jamila H. Champsi, Jennifer B. Lai, Suk I. Seo, Laura C. Gittleman, David J. Witt

Publikováno v: Public Health Reports. 133:452-460

Objectives: The cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may contribute to treatment disparities. However, few data exist on factors associated with DAA initiation. Methods: We conducted a retrospective coho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd16897b0e8ae9f3c2d638d9c2d16d70
https://doi.org/10.1177/0033354918772059

Zobrazit plný text záznamu

Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System

Autor: Mary Patricia Pauly, Jennifer B. Lai, Suk I. Seo, Maxwell A. Witt, Michael Allerton, David J. Witt, Joanna Ready

Publikováno v: Drugs. 77:313-318

Second-generation direct-acting antiviral agents are integral to treatment of hepatitis C (HCV) infection. Eight-week courses of ledipasvir/sofosbuvir (LDV/SOF) have been supported in some studies, but data are limited on efficacy in real-world use.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54e9211f14e89b42152dd3ea78e021ed
https://doi.org/10.1007/s40265-016-0684-y

Zobrazit plný text záznamu

Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system

Autor: Daniel G. Korn, Michael J. Silverberg, Scott Chamberland, Varun Saxena, Suk I. Seo, David J. Witt, Jamila H. Champsi, Julia L. Marcus, Laura C. Gittleman, Jennifer B. Lai, Leo B. Hurley, Jennifer O Lam, Joanna Ready, Charles P. Quesenberry

Publikováno v: International journal of STDAIDS. 30(7)

U.S. guidelines recommend that patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) be prioritized for HCV treatment with direct-acting antiviral agents (DAAs), but the high cost of DAAs may contribute to disparitie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3350b1cc6b3e401c27626492470e8319
https://pubmed.ncbi.nlm.nih.gov/31046611

Zobrazit plný text záznamu

Prevalence of Spontaneous Clearance of Hepatitis C Virus Infection Doubled From 1998 to 2017

Autor: Scott Chamberland, David R. Witt, C. Bradley Hare, Varun Saxena, Suk I. Seo, Michael J. Silverberg, Mary Patricia Pauly, Joanna Ready, Julia L. Marcus, Leo B. Hurley, Daniel G. Korn, Jamila H. Champsi, Jennifer B. Lai

Publikováno v: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 18(2)

Strategic planning for hepatitis C virus (HCV) screening and treatment requires up-to-date information on the prevalence of HCV spontaneous clearance. Published estimates of HCV spontaneous clearance range from 15% to 60%.1-3 We conducted an observat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1097e3e8d0adef3b2f7022d4c1b50de
https://pubmed.ncbi.nlm.nih.gov/31009792

Zobrazit plný text záznamu

Racial/Ethnic and Socioeconomic Disparities in Initiation of Direct-Acting Antiviral Agents for Hepatitis C Virus in an Insured Population

Autor: Michael J. Silverberg, Leo B. Hurley, Julia L. Marcus, Scott Chamberland, Laura C. Gittleman, Joanna Ready, David R. Witt, Suk I. Seo, Charles P. Quesenberry, Jamila H. Champsi, Jennifer B. Lai, Daniel G. Korn, Varun Saxena

Publikováno v: Open Forum Infectious Diseases

Background The high cost of direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection may present a barrier to access, thus contributing to disparities in treatment. However, few real-world data exist on factors associated with DAA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4540b5ac2997a595065173dc743d9b44
https://doi.org/10.1093/ofid/ofx163.380

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání